Skip to main content
Top
Published in: Diabetes Therapy 5/2019

Open Access 01-10-2019 | Insulins | Commentary

Do-It-Yourself Artificial Pancreas Systems in Type 1 Diabetes: Perspectives of Two Adult Users, a Caregiver and Three Physicians

Authors: Dominic C. Marshall, Melissa Holloway, Mendy Korer, James Woodman, Anna Brackenridge, Sufyan Hussain

Published in: Diabetes Therapy | Issue 5/2019

Login to get access

Abstract

Advances in continuous glucose monitoring and insulin pumps have allowed people with type 1 diabetes (T1D) and caregivers to accurately and continuously measure their glucose levels and make adjustments to insulin infusion. In recent years, algorithms for subcutaneous insulin dosing have been developed that can respond to changes in glucose in an automated fashion and “close the loop”. At present, a first-generation ‘hybrid closed-loop’, ‘artificial pancreas’ or ‘automated insulin dosing’ system, Medtronic 670G, is available commercially. Further systems are in clinical trials. Frustrated by the slow pace of innovation, people affected by diabetes have united online under the hashtag ‘#WeAreNotWaiting,’ to disseminate open-source diabetes technologies. One dimension of #WeAreNotWaiting is “looping” with a do-it-yourself artificial pancreas. Here we provide the perspectives of two adults with T1D, the parent of a child with T1D and three physicians who detail their experience with these systems. These personal and clinical perspectives highlight very clear metabolic and psychological benefits of these systems in real-world settings.
Literature
5.
go back to reference Lewis D, Leibrand S, OpenAPS Community. Real-world use of open source artificial pancreas systems. J Diabetes Sci Technol. 2016;10(6):1411.CrossRef Lewis D, Leibrand S, OpenAPS Community. Real-world use of open source artificial pancreas systems. J Diabetes Sci Technol. 2016;10(6):1411.CrossRef
6.
go back to reference Litchman ML, Lewis D, Kelly LA, et al. Twitter analysis of #OpenAPS DIY artificial pancreas technology use suggests improved A1C and quality of life. J Diabetes Sci Technol. 2019;13:164–70.CrossRef Litchman ML, Lewis D, Kelly LA, et al. Twitter analysis of #OpenAPS DIY artificial pancreas technology use suggests improved A1C and quality of life. J Diabetes Sci Technol. 2019;13:164–70.CrossRef
9.
go back to reference Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316:1407–8.CrossRef Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316:1407–8.CrossRef
11.
go back to reference Barnard KD, Ziegler R, Klonoff DC, et al. Open source closed-loop insulin delivery systems: a clash of cultures or merging of diverse approaches? J Diabetes Sci Technol. 2018;12:1223–6.CrossRef Barnard KD, Ziegler R, Klonoff DC, et al. Open source closed-loop insulin delivery systems: a clash of cultures or merging of diverse approaches? J Diabetes Sci Technol. 2018;12:1223–6.CrossRef
Metadata
Title
Do-It-Yourself Artificial Pancreas Systems in Type 1 Diabetes: Perspectives of Two Adult Users, a Caregiver and Three Physicians
Authors
Dominic C. Marshall
Melissa Holloway
Mendy Korer
James Woodman
Anna Brackenridge
Sufyan Hussain
Publication date
01-10-2019
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 5/2019
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-019-00679-y

Other articles of this Issue 5/2019

Diabetes Therapy 5/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine